<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: High-dose therapy (HDT) with autologous blood stem cell transplantation (ASCT) has become the therapy of choice for patients with specific hematologic <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> after HDT with stem cell support is of relatively short duration, complications may be severe and life-threatening </plain></SENT>
<SENT sid="2" pm="."><plain>In unselected patients with hematologic and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, only few data have been published regarding complications </plain></SENT>
<SENT sid="3" pm="."><plain>We therefore analyzed the rate of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and toxicity in patients with different <z:hpo ids='HP_0002664'>neoplasms</z:hpo> undergoing HDT and ASCT </plain></SENT>
<SENT sid="4" pm="."><plain>PATIENTS AND METHODS: From 6/96 to 12/99 42 patients received 54 HDT and ASCT (nine tandem transplants and one triple transplant) </plain></SENT>
<SENT sid="5" pm="."><plain>The median age was 55 years (range 25-74 years) with equal sex distribution </plain></SENT>
<SENT sid="6" pm="."><plain>30 patients suffered from <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> and twelve from <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infections</z:e> were the major cause for complications followed by mucositis, pain and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In four patients a positive cytomegalovirus polymerase chain reaction (CMV-PCR) was detected </plain></SENT>
<SENT sid="9" pm="."><plain>In two patients this positive test result was accompanied by clinical symptoms of <z:e sem="disease" ids="C0010823" disease_type="Disease or Syndrome" abbrv="">CMV infection</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>One patient developed <z:mp ids='MP_0006050'>lung fibrosis</z:mp> due to <z:chebi fb="0" ids="28901">busulfan</z:chebi> (WHO 4 degrees) and additionally a <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>) of the liver (WHO 4 degrees) </plain></SENT>
<SENT sid="11" pm="."><plain>Two patients (4%) died due to CMV <z:hpo ids='HP_0002090'>pneumonia</z:hpo> and multiple organ failure after idiopathic <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, respectively </plain></SENT>
<SENT sid="12" pm="."><plain>Four patients developed secondary <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (two patients <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, two patients <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>) </plain></SENT>
<SENT sid="13" pm="."><plain>Three of them had been heavily pretreated </plain></SENT>
<SENT sid="14" pm="."><plain>We further analyzed whether the following parameters had an influence on the rate of complications: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> diagnosis (hematologic vs. solid), number of pretreatment protocols (&lt; 2 vs. &gt; or = 2), CD34+ cell count (&lt; median CD34+ cell count vs. &gt; or = median CD34+ cell count), age (&lt; or = 55 years vs. &gt; 55 years), mucositis (WHO 1-2 degrees vs. 3-4 degrees) and conditioning regimen (myeloablative vs. myelosuppressive) </plain></SENT>
<SENT sid="15" pm="."><plain>The <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> rate was higher in patients receiving myeloablative therapy compared to patients with myelosuppressive conditioning and the platelet count recovery was slower </plain></SENT>
<SENT sid="16" pm="."><plain>In patients receiving a higher CD34+ cell count, time until platelets reached &gt; 50/nl was shorter than in patients with a lower CD34+ cell count </plain></SENT>
<SENT sid="17" pm="."><plain>Patients with &gt; or = 2 pretreatment protocols had a higher <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> rate than patients with &lt; 2 pretreatments </plain></SENT>
<SENT sid="18" pm="."><plain>Patients suffering from severe mucositis (WHO 3-4 degrees) exhibited a slower platelet recovery and a higher <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> rate </plain></SENT>
<SENT sid="19" pm="."><plain>No difference was noted in the complication rate for the other parameters (<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> diagnosis, age) </plain></SENT>
<SENT sid="20" pm="."><plain>CONCLUSION: Complication rate and mortality in this <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> patient group were not different from the data of other authors describing selected patients receiving a uniform conditioning regimen or having a distinct disease </plain></SENT>
<SENT sid="21" pm="."><plain>The complication rate is influenced by the number of pretreatment protocols, conditioning regimens and the number of transplanted CD34+ cells </plain></SENT>
</text></document>